PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cambridge Healthtech Institute

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pharma Leader, Declan Doogan to Keynote CHI’s Conference on Phase III Clinical Trials - Amarin’s CMO to lead line-up of thought leaders at Cambridge Healthtech Institute’s executive and scientific forum - HealthTech.com
Pharma Leader, Declan Doogan to Keynote CHI’s Conference on Phase III Clinical Trials

 

NewswireToday - /newswire/ - Needham, MA, United States, 2011/12/22 - Amarin’s CMO to lead line-up of thought leaders at Cambridge Healthtech Institute’s executive and scientific forum - HealthTech.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cambridge Healthtech Institute (CHI) today announced that Amarin’s CMO Declan Doogan, M.D., will deliver the keynote presentation at CHI’s BioPharma Strategy Series’ executive and scientific forum,“Phase III Clinical Trials: Strategic Decisions for Successful Drugs,” to take place on March 12-13, 2012 at the Crowne Plaza Hotel in Philadelphia, PA.

Talk title: Have We Lost the Plot in Phase III Development?
Abstract: In 2010 twenty one NDA/NBAs were approved. The ratio of NME:NBE was 15:6. A decade earlier 29 entities were approved; NME:NBE ratio was 27:2. The rapid evolution of the science base has enabled access to new targets, but the failure rate has grown dramatically too. This can be traced back to poor decision making. The main reason is that candidates were inappropriately nominated at the end of Phase II or did not have the appropriate characterization during Phase II.

Dr. Doogan has been part of pharmaceutical R&D for most of his professional life, starting first in the Netherlands as a project physician. He joined Pfizer in 1982, where he was in charge of the sertraline (Zoloft) clinical development program. He has held a number of senior positions in R&D in the US, UK, China and Japan. He retired from Pfizer in April 2007 where he was Senior Vice President World Development. Subsequently, Declan joined Irish pharmaceutical outfit, Amarin, to help re-calibrate its R&D focus from CNS to its current cardiovascular program.

Dr. Doogan holds a number of executive board appointments principally in the fields of pharmaceutical R&D and life science investments. He is also a Visiting Professor at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). He is interested not only in the scientific aspects of drug development but also in defining new strategies to improve yield and effectiveness in human drug development. He is also involved in charities such as the Haitian Health Foundation, the Pulmonary Vascular Research Institute and Odessey, a cancer charity. Doogan is also president and co-founder of health focused social network, WeAre.Us.

Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the UK.

For more information about the Phase III Clinical Trials conference, visit healthtech.com/ph3.

To inquire about sponsoring and/or exhibiting, contact Carol Dinerstein, 781-972-5471, dinerstein[.]healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding[.]healthtech.com.

About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cambridge Healthtech Institute

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pharma Leader, Declan Doogan to Keynote CHI’s Conference on Phase III Clinical Trials

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: James Prudhomme - HealthTech.com 
781-972-5400 jprudhomme[.]healthtech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cambridge Healthtech Institute securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cambridge Healthtech Institute / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)